Nutraceuticals: Potential for chondroprotection and molecular targeting of osteoarthritis

International Journal of Molecular Sciences

Volumn 14, Issue 11, 2013, Pages 23063-23085

  Leong, Daniel J ^a   Choudhury, Marwa ^a   Hirsh, David M ^a   Hardin, John A ^a   Cobelli, Neil J ^a   Sun, Hui B ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Molecular targets; Nutraceuticals; Osteoarthritis

Indexed keywords

ALOE VERA EXTRACT; ALPHA TOCOPHEROL; ASCORBIC ACID; BIOFLAVONOID; BOSWELLIA SERRATA EXTRACT; BROMELAIN; CAESALPINIA SAPPAN EXTRACT; CAPSAICIN; COLLAGEN HYDROLYSATE; DIMETHYL SULFONE; EDIBLE BIRD NEST EXTRACT; FLAVONOID; GARLIC EXTRACT; GENISTEIN; GINGER EXTRACT; GREEN LIPPED MUSSEL EXTRACT; GREEN TEA EXTRACT; LACTOBACILLUS CASEI EXTRACT; NICOTINAMIDE; NUTRACEUTICAL; PIASCLEDINE; PLACEBO; POLYPHENOL DERIVATIVE; POLYUNSATURATED FATTY ACID; POMEGRANATE EXTRACT; PROTEIN HYDROLYSATE; ROSEHIP POWDER; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRALGIA; ARTICLE; CHONDROPROTECTION; DISEASE SEVERITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; KNEE PAIN; MOLECULARLY TARGETED THERAPY; NONHUMAN; OSTEOARTHRITIS; PAIN; RISK REDUCTION;

DIETARY SUPPLEMENTS; FLAVONOIDS; GINGER; HUMANS; MOLECULAR TARGETED THERAPY; OSTEOARTHRITIS; OXIDATIVE STRESS; POLYPHENOLS; PUNICACEAE; TEA;

EID: 84888158554     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141123063     Document Type: Article

References (167)

1. Lawrence, R.C.; Felson, D.T.; Helmick, C.G.; Arnold, L.M.; Choi, H.; Deyo, R.A.; Gabriel, S.; Hirsch, R.; Hochberg, M.C.; Hunder, G.G.; et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58, 26-35.
2. Suri, P.; Morgenroth, D.C.; Hunter, D.J. Epidemiology of osteoarthritis and associated comorbidities. PM R 2012, 4, S10-S19.
3. Kotlarz, H.; Gunnarsson, C.L.; Fang, H.; Rizzo, J.A. Insurer and out-of-pocket costs of osteoarthritis in the US: Evidence from national survey data. Arthritis Rheum 2009, 60, 3546-3553.
4. Loeser, R.F.; Goldring, S.R.; Scanzello, C.R.; Goldring, M.B. Osteoarthritis: A disease of the joint as an organ. Arthritis Rheum 2012, 64, 1697-1707.
5. Burr, D.B.; Gallant, M.A. Bone remodelling in osteoarthritis. Nat. Rev. Rheumatol. 2012, 8, 665-673.
6. Le Graverand-Gastineau, M.P. Disease modifying osteoarthritis drugs: Facing development challenges and choosing molecular targets. Curr. Drug Targets 2010, 11, 528-535.
7. Evans, C.H.; Ghivizzani, S.C.; Robbins, P.D. Getting arthritis gene therapy into the clinic. Nat. Rev. Rheumatol. 2011, 7, 244-249.
8. Heinegard, D.; Saxne, T. The role of the cartilage matrix in osteoarthritis. Nat. Rev. Rheumatol. 2011, 7, 50-56.
9. Sun, H.B. Mechanical loading, cartilage degradation, and arthritis. Ann. N. Y. Acad. Sci. 2010, 1211, 37-50.
10. Hashimoto, M.; Nakasa, T.; Hikata, T.; Asahara, H. Molecular network of cartilage homeostasis and osteoarthritis. Med. Res. Rev. 2008, 28, 464-481.
11. Cheng, D.S.; Visco, C.J. Pharmaceutical therapy for osteoarthritis. PM&R 2012, 4, S82-S88.
12. Patrignani, P.; Tacconelli, S.; Bruno, A.; Sostres, C.; Lanas, A. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Exp. Rev. Clin. Pharm. 2011, 4, 605-621.
13. Henrotin, Y.; Lambert, C.; Couchourel, D.; Ripoll, C.; Chiotelli, E. Nutraceuticals: Do they represent a new era in the management of osteoarthritis?-A narrative review from the lessons taken with five products. Osteoarthr. Cartilage 2011, 19, 1-21.
14. Akhtar, N.; Haqqi, T.M. Current nutraceuticals in the management of osteoarthritis: A review. Ther. Adv. Musculoskelet Dis. 2012, 4, 181-207.
15. Shen, C.L.; Smith, B.J.; Lo, D.F.; Chyu, M.C.; Dunn, D.M.; Chen, C.H.; Kwun, I.S. Dietary polyphenols and mechanisms of osteoarthritis. J. Nutr. Biochem. 2012, 23, 1367-1377.
16. Guimaraes, A.G.; Xavier, M.A.; de Santana, M.T.; Camargo, E.A.; Santos, C.A.; Brito, F.A.; Barreto, E.O.; Cavalcanti, S.C.; Antoniolli, A.R.; Oliveira, R.C.; et al. Carvacrol attenuates mechanical hypernociception and inflammatory response. Naunyn. Schmiedebergs. Arch. Pharmacol. 2012, 385, 253-263.
17. Cavalcante Melo, F.H.; Rios, E.R.; Rocha, N.F.; Cito Mdo, C.; Fernandes, M.L.; De Sousa, D.P.; De Vasconcelos, S.M.; De Sousa, F.C. Antinociceptive activity of carvacrol(5-isopropyl-2-methylphenol) in mice. J. Pharm. Pharmacol. 2012, 64, 1722-1729.
18. Guimaraes, A.G.; Oliveira, G.F.; Melo, M.S.; Cavalcanti, S.C.; Antoniolli, A.R.; Bonjardim, L.R.; Silva, F.A.; Santos, J.P.; Rocha, R.F.; et al. Bioassay-guided evaluation of antioxidant and antinociceptive activities of carvacrol. Basic Clin. Pharmacol. Toxicol. 2010, 107, 949-957.
19. Henrotin, Y.; Clutterbuck, A.L.; Allaway, D.; Lodwig, E.M.; Harris, P.; Mathy-Hartert, M.; Shakibaei, M.; Mobasheri, A. Biological actions of curcumin on articular chondrocytes. Osteoarthr. Cartilage 2010, 18, 141-149.
20. Sreejayan Rao, M.N. Nitric oxide scavenging by curcuminoids. J. Pharm. Pharmacol. 1997, 49, 105-107.
21. Black, C.; Clar, C.; Henderson, R.; MacEachern, C.; McNamee, P.; Quayyum, Z.; Royle, P.; Thomas, S. The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: A systematic review and economic evaluation. Health Tech. Assess. 2009, 13, 1-148.
22. Roughley, P.J. The structure and function of cartilage proteoglycans. Eur. Cell Mater. 2006, 12, 92-101.
23. Clegg, D.O.; Reda, D.J.; Harris, C.L.; Klein, M.A.; O'Dell, J.R.; Hooper, M.M.; Bradley, J.D.; Bingham, C.O., 3rd; Weisman, M.H.; Jackson, C.G.; et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. 2006, 354, 795-808.
24. Sawitzke, A.D.; Shi, H.; Finco, M.F.; Dunlop, D.D.; Bingham, C.O., 3rd; Harris, C.L.; Singer, N.G.; Bradley, J.D.; Silver, D.; Jackson, C.G.; et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: A report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum. 2008, 58, 3183-3191.
25. Sawitzke, A.D.; Shi, H.; Finco, M.F.; Dunlop, D.D.; Harris, C.L.; Singer, N.G.; Bradley, J.D.; Silver, D.; Jackson, C.G.; Lane, N.E.; et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann. Rheum. Dis. 2010, 69, 1459-1464.
26. Gupta, P.K.; Samarakoon, S.M.; Chandola, H.M.; Ravishankar, B. Clinical evaluation of Boswellia serrata(Shallaki) resin in the management of Sandhivata(osteoarthritis). Ayu 2011, 32, 478-482.
27. Krishnaraju, A.V.; Sundararaju, D.; Vamsikrishna, U.; Suryachandra, R.; Machiraju, G.; Sengupta, K.; Trimurtulu, G. Safety and toxicological evaluation of Aflapin: A novel Boswellia-derived anti-inflammatory product. Toxicol. Mech. Method 2010, 20, 556-563.
28. Kimmatkar, N.; Thawani, V.; Hingorani, L.; Khiyani, R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee-A randomized double blind placebo controlled trial. Phytomedicine 2003, 10, 3-7.
29. Sengupta, K.; Kolla, J.N.; Krishnaraju, A.V.; Yalamanchili, N.; Rao, C.V.; Golakoti, T.; Raychaudhuri, S.; Raychaudhuri, S.P. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: A novel Boswellia serrata extract. Mol. Cell Biochem. 2011, 354, 189-197.
30. Brien, S.; Lewith, G.; Walker, A.F.; Middleton, R.; Prescott, P.; Bundy, R. Bromelain as an adjunctive treatment for moderate-to-severe osteoarthritis of the knee: A randomized placebo-controlled pilot study. QJM 2006, 99, 841-850.
31. Brien, S.; Lewith, G.; Walker, A.; Hicks, S.M.; Middleton, D. Bromelain as a treatment for osteoarthritis: A review of clinical studies. Evid. based Compl. Alternative Med. 2004, 1, 251-257.
32. Wu, S.Q.; Otero, M.; Unger, F.M.; Goldring, M.B.; Phrutivorapongkul, A.; Chiari, C.; Kolb, A.; Viernstein, H.; Toegel, S. Anti-inflammatory activity of an ethanolic Caesalpinia sappan extract in human chondrocytes and macrophages. J. Ethnopharmacol. 2011, 138, 364-372.
33. Toegel, S.; Wu, S.Q.; Otero, M.; Goldring, M.B.; Leelapornpisid, P.; Chiari, C.; Kolb, A.; Unger, F.M.; Windhager, R.; Viernstein, H. Caesalpinia sappan extract inhibits IL1beta-mediated overexpression of matrix metalloproteinases in human chondrocytes. Genes Nutr. 2012, 7, 307-318.
34. Kosuwon, W.; Sirichatiwapee, W.; Wisanuyotin, T.; Jeeravipoolvarn, P.; Laupattarakasem, W. Efficacy of symptomatic control of knee osteoarthritis with 0.0125% of capsaicin versus placebo. J. Med. Assoc. Thailand 2010, 93, 1188-1195.
35. Remadevi, R.; Szallisi, A. Adlea(ALGRX-4975), an injectable capsaicin(TRPV1 receptor agonist) formulation for longlasting pain relief. IDrugs 2008, 11, 120-132.
36. McKay, L.; Gemmell, H.; Jacobson, B.; Hayes, B. Effect of a topical herbal cream on the pain and stiffness of osteoarthritis: A randomized double-blind, placebo-controlled clinical trial. J. Clin. Rheumatol. 2003, 9, 164-169.
37. Engler, A.; Aeschlimann, A.; Simmen, B.R.; Michel, B.A.; Gay, R.E.; Gay, S.; Sprott, H. Expression of transient receptor potential vanilloid 1(TRPV1) in synovial fibroblasts from patients with osteoarthritis and rheumatoid arthritis. Biochem. Biophys. Res. Commun. 2007, 359, 884-888.
38. Piscoya, J.; Rodriguez, Z.; Bustamante, S.A.; Okuhama, N.N.; Miller, M.J.; Sandoval, M. Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: Mechanisms of action of the species Uncaria guianensis. Inflamm. Res. 2001, 50, 442-448.
39. Rosenbaum, C.C.; O'Mathuna, D.P.; Chavez, M.; Shields, K. Antioxidants and antiinflammatory dietary supplements for osteoarthritis and rheumatoid arthritis. Altern. Ther. Health Med. 2010, 16, 32-40.
40. Olsen, N.J.; Branch, V.K.; Jonnala, G.; Seskar, M.; Cooper, M. Phase 1, placebo-controlled, dose escalation trial of chicory root extract in patients with osteoarthritis of the hip or knee. BMC Musculoskelet. Disord. 2010, 11, 156.
41. Cavin, C.; Delannoy, M.; Malnoe, A.; Debefve, E.; Touche, A.; Courtois, D.; Schilter, B. Inhibition of the expression and activity of cyclooxygenase-2 by chicory extract. Biochem. Biophys. Res. Commun. 2005, 327, 742-749.
42. Schmidt, B.M.; Ilic, N.; Poulev, A.; Raskin, I. Toxicological evaluation of a chicory root extract. Food Chem. Toxicol. 2007, 45, 1131-1139.
43. Chen, W.P.; Tang, J.L.; Bao, J.P.; Hu, P.F.; Yu, C.; Shi, Z.L.; Wu, L.D. Effects of diallyl sulphide in chondrocyte and cartilage in experimental osteoarthritis in rabbit. Phytother. Res. 2011, 25, 351-356.
44. Lee, H.S.; Lee, C.H.; Tsai, H.C.; Salter, D.M. Inhibition of cyclooxygenase 2 expression by diallyl sulfide on joint inflammation induced by urate crystal and IL-1beta. Osteoarthr. Cartilage 2009, 17, 91-99.
45. Lai, J.N.; Chen, H.J.; Chen, C.C.; Lin, J.H.; Hwang, J.S.; Wang, J.D. Duhuo jisheng tang for treating osteoarthritis of the knee: A prospective clinical observation. Chinese Med. 2007, 2, 4.
46. Chantre, P.; Cappelaere, A.; Leblan, D.; Guedon, D.; Vandermander, J.; Fournie, B. Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine 2000, 7, 177-183.
47. Chrubasik, S.; Thanner, J.; Kunzel, O.; Conradt, C.; Black, A.; Pollak, S. Comparison of outcome measures during treatment with the proprietary Harpagophytum extract doloteffin in patients with pain in the lower back, knee or hip. Phytomedicine 2002, 9, 181-194.
48. Chrubasik, J.E.; Roufogalis, B.D.; Chrubasik, S. Evidence of effectiveness of herbal antiinflammatory drugs in the treatment of painful osteoarthritis and chronic low back pain. Phytother. Res. 2007, 21, 675-683.
49. Fiebich, B.L.; Munoz, E.; Rose, T.; Weiss, G.; McGregor, G.P. Molecular targets of the antiinflammatory Harpagophytum procumbens(devil's claw): Inhibition of TNFalpha and COX-2 gene expression by preventing activation of AP-1. Phytother. Res. 2012, 26, 806-811.
50. Sumantran, V.N.; Kulkarni, A.; Chandwaskar, R.; Harsulkar, A.; Patwardhan, B.; Chopra, A.; Wagh, U.V. Chondroprotective potential of fruit extracts of Phyllanthus emblica in Osteoarthritis. Evid. Base. Compl. Alternative Med. 2008, 5, 329-335.
51. Uehleke, B.; Muller, J.; Stange, R.; Kelber, O.; Melzer, J. Willow bark extract STW 33-I in the long-term treatment of outpatients with rheumatic pain mainly osteoarthritis or back pain. Phytomedicine 2013, 20, 980-984.
52. Schmid, B.; Ludtke, R.; Selbmann, H.K.; Kotter, I.; Tschirdewahn, B.; Schaffner, W.; Heide, L. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: Randomized placebo-controlled, double blind clinical trial. Phytother. Res. 2001, 15, 344-350.
53. Cowan, D. Oral Aloe vera as a treatment for osteoarthritis: A summary. Brit. J. Comm. Nur. 2010, 15, 280-282.
54. Christensen, R.; Bartels, E.M.; Astrup, A.; Bliddal, H. Symptomatic efficacy of avocado-soybean unsaponifiables(ASU) in osteoarthritis(OA) patients: A meta-analysis of randomized controlled trials. Osteoarthr. Cartilage 2008, 16, 399-408.
55. Appelboom, T.; Schuermans, J.; Verbruggen, G.; Henrotin, Y.; Reginster, J.Y. Symptoms modifying effect of avocado/soybean unsaponifiables(ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand. J. Rheumatol. 2001, 30, 242-247.
56. Boileau, C.; Martel-Pelletier, J.; Caron, J.; Msika, P.; Guillou, G.B.; Baudouin, C.; Pelletier, J.P. Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: Inhibition of nitric oxide synthase and matrix metalloproteinase-13. Arthritis Res. Ther. 2009, 11, R41.
57. Au, R.Y.; Al-Talib, T.K.; Au, A.Y.; Phan, P.V.; Frondoza, C.G. Avocado soybean unsaponifiables(ASU) suppress TNF-alpha, IL-1beta, COX-2, iNOS gene expression, and prostaglandin E2 and nitric oxide production in articular chondrocytes and monocyte/macrophages. Osteoarthr. Cartilage 2007, 15, 1249-1255.
58. Scorei, R.I.; Rotaru, P. Calcium fructoborate-Potential anti-inflammatory agent. Biol. Trace Element Res. 2011, 143, 1223-1238.
59. Bello, A.E.; Oesser, S. Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: A review of the literature. Curr. Med. Res. Opin. 2006, 22, 2221-2232.
60. Van Vijven, J.P.; Luijsterburg, P.A.; Verhagen, A.P.; van Osch, G.J.; Kloppenburg, M.; Bierma-Zeinstra, S.M. Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis: A systematic review. Osteoarthr. Cartilage 2012, 20, 809-821.
61. Chua, K.H.; Lee, T.H.; Nagandran, K.; Md Yahaya, N.H.; Lee, C.T.; Tjih, E.T.; Abdul Aziz, R. Edible Bird's nest extract as a chondro-protective agent for human chondrocytes isolated from osteoarthritic knee: In vitro study. BMC Compl. Alternative Med. 2013, 13, 19.
62. Hooshmand, S.; Soung do, Y.; Lucas, E.A.; Madihally, S.V.; Levenson, C.W.; Arjmandi, B.H. Genistein reduces the production of proinflammatory molecules in human chondrocytes. J. Nutr. Biochem. 2007, 18, 609-614.
63. Coulson, S.; Vecchio, P.; Gramotnev, H.; Vitetta, L. Green-lipped mussel(Perna canaliculus) extract efficacy in knee osteoarthritis and improvement in gastrointestinal dysfunction: A pilot study. Inflammopharmacology 2012, 20, 71-76.
64. Halpern, G.M. Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus(Lyprinol). Allerg. Immunol. 2000, 32, 272-278.
65. So, J.S.; Song, M.K.; Kwon, H.K.; Lee, C.G.; Chae, C.S.; Sahoo, A.; Jash, A.; Lee, S.H.; Park, Z.Y.; Im, S.H. Lactobacillus casei enhances type II collagen/glucosamine-mediated suppression of inflammatory responses in experimental osteoarthritis. Life Sci. 2011, 88, 358-366.
66. Kim, L.S.; Axelrod, L.J.; Howard, P.; Buratovich, N.; Waters, R.F. Efficacy of methylsulfonylmethane(MSM) in osteoarthritis pain of the knee: A pilot clinical trial. Osteoarthr. Cartilage 2006, 14, 286-294.
67. Fox, R.B.; Fox, W.K. Dimethyl sulfoxide prevents hydroxyl radical-mediated depolymerization of hyaluronic acid. Ann. N. Y. Acad. Sci. 1983, 411, 14-18.
68. Parcell, S. Sulfur in human nutrition and applications in medicine. Altern. Med. Rev. 2002, 7, 22-44.
69. Baker, K.R.; Matthan, N.R.; Lichtenstein, A.H.; Niu, J.; Guermazi, A.; Roemer, F.; Grainger, A.; Nevitt, M.C.; Clancy, M.; Lewis, C.E.; et al. Association of plasma n-6 and n-3 polyunsaturated fatty acids with synovitis in the knee: The MOST study. Osteoarthr. Cartilage 2012, 20, 382-387.
70. Curtis, C.L.; Rees, S.G.; Little, C.B.; Flannery, C.R.; Hughes, C.E.; Wilson, C.; Dent, C.M.; Otterness, I.G.; Harwood, J.L.; Caterson, B. Pathologic indicators of degradation and inflammation in human osteoarthritic cartilage are abrogated by exposure to n-3 fatty acids. Arthritis Rheum. 2002, 46, 1544-1553.
71. Knott, L.; Avery, N.C.; Hollander, A.P.; Tarlton, J.F. Regulation of osteoarthritis by omega-3(n-3) polyunsaturated fatty acids in a naturally occurring model of disease. Osteoarthr. Cartilage 2011, 19, 1150-1157.
72. Kim, J.; Lee, E.Y.; Koh, E.M.; Cha, H.S.; Yoo, B.; Lee, C.K.; Lee, Y.J.; Ryu, H.; Lee, K.H.; Song, Y.W. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: An 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. Clin. Ther 2009, 31, 2860-2872.
73. Najm, W.I.; Reinsch, S.; Hoehler, F.; Tobis, J.S.; Harvey, P.W. S-adenosyl methionine(SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]. BMC Musculoskelet Disord. 2004, 5, 6.
74. Bradley, J.D.; Flusser, D.; Katz, B.P.; Schumacher, H.R., Jr.; Brandt, K.D.; Chambers, M.A.; Zonay, L.J. A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine(SAM) followed by oral SAM therapy in patients with knee osteoarthritis. J. Rheumatol. 1994, 21, 905-911.
75. Harmand, M.F.; Vilamitjana, J.; Maloche, E.; Duphil, R.; Ducassou, D. Effects of S-adenosylmethionine on human articular chondrocyte differentiation. An in vitro study. Am. J. Med. 1987, 83, 48-54.
76. Barcelo, H.A.; Wiemeyer, J.C.; Sagasta, C.L.; Macias, M.; Barreira, J.C. Effect of S-adenosylmethionine on experimental osteoarthritis in rabbits. Am. J. Med.1987, 83, 55-59.
77. Jonas, W.B.; Rapoza, C.P.; Blair, W.F. The effect of niacinamide on osteoarthritis: A pilot study. Inflamm. Res. 1996, 45, 330-334.
78. Clark, A.G.; Rohrbaugh, A.L.; Otterness, I.; Kraus, V.B. The effects of ascorbic acid on cartilage metabolism in guinea pig articular cartilage explants. Matrix Biol. 2002, 21, 175-184.
79. McAlindon, T.; LaValley, M.; Schneider, E.; Nuite, M.; Lee, J.Y.; Price, L.L.; Lo, G.; Dawson-Hughes, B. Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: A randomized controlled trial. JAMA 2013, 309, 155-162.
80. Sanghi, D.; Mishra, A.; Sharma, A.C.; Singh, A.; Natu, S.M.; Agarwal, S.; Srivastava, R.N. Does vitamin D Improve osteoarthritis of the knee: A randomized controlled pilot trial. Clin. Orthop. Relat. Res. 2013, 471, 3556-3562.
81. Blankenhorn, G. Clinical effectiveness of Spondyvit(vitamin E) in activated arthroses. A multicenter placebo-controlled double-blind study. Zeitschrift fur Orthopadie und ihre Grenzgebiete 1986, 124, 340-343.
82. Brand, C.; Snaddon, J.; Bailey, M.; Cicuttini, F. Vitamin E is ineffective for symptomatic relief of knee osteoarthritis: A six month double blind, randomised, placebo controlled study. Ann. Rheum. Dis. 2001, 60, 946-949.
83. Dixon, R.A.; Xie, D.Y.; Sharma, S.B. Proanthocyanidins-A final frontier in flavonoid research? New Phytol. 2005, 165, 9-28.
84. Miyake, M.; Ide, K.; Sasaki, K.; Matsukura, Y.; Shijima, K.; Fujiwara, D. Oral administration of highly oligomeric procyanidins of Jatoba reduces the severity of collagen-induced arthritis. Biosci. Biotechnol. Biochem. 2008, 72, 1781-1788.
85. Hadipour-Jahromy, M.; Mozaffari-Kermani, R. Chondroprotective effects of pomegranate juice on monoiodoacetate-induced osteoarthritis of the knee joint of mice. Phytother. Res. 2010, 24, 182-185.
86. Bliddal, H.; Rosetzsky, A.; Schlichting, P.; Weidner, M.S.; Andersen, L.A.; Ibfelt, H.H.; Christensen, K.; Jensen, O.N.; Barslev, J. A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthr. Cartilage 2000, 8, 9-12.
87. Altman, R.D.; Marcussen, K.C. Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis Rheum. 2001, 44, 2531-2538.
88. Kulkarni, R.R.; Patki, P.S.; Jog, V.P.; Gandage, S.G.; Patwardhan, B. Treatment of osteoarthritis with a herbomineral formulation: A double-blind, placebo-controlled, cross-over study. J. Ethnopharmacol.1991, 33, 91-95.
89. Christensen, R.; Bartels, E.M.; Altman, R.D.; Astrup, A.; Bliddal, H. Does the hip powder of Rosa canina(rosehip) reduce pain in osteoarthritis patients? -A meta-analysis of randomized controlled trials. Osteoarthr. Cartilage 2008, 16, 965-972.
90. Csaki, C.; Mobasheri, A.; Shakibaei, M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: Inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res. Ther. 2009, 11, R165.
91. Doss, M.X.; Potta, S.P.; Hescheler, J.; Sachinidis, A. Trapping of growth factors by catechins: A possible therapeutical target for prevention of proliferative diseases. J. Nutr. Biochem. 2005, 16, 259-266.
92. Marotte, H.; Ruth, J.H.; Campbell, P.L.; Koch, A.E.; Ahmed, S. Green tea extract inhibits chemokine production, but up-regulates chemokine receptor expression, in rheumatoid arthritis synovial fibroblasts and rat adjuvant-induced arthritis. Rheumatology 2010, 49, 467-479.
93. Seeram, N.P.; Adams, L.S.; Henning, S.M.; Niu, Y.; Zhang, Y.; Nair, M.G.; Heber, D. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J. Nutr. Biochem. 2005, 16, 360-367.
94. Ahmed, S.; Wang, N.; Hafeez, B.B.; Cheruvu, V.K.; Haqqi, T.M. Punica granatum L. extract inhibits IL-1beta-induced expression of matrix metalloproteinases by inhibiting the activation of MAP kinases and NF-kappaB in human chondrocytes in vitro.J. Nutr. 2005, 135, 2096-2102.
95. White, B. Ginger: An overview. Am. Fam. Physician 2007, 75, 1689-1691.
96. Mathy-Hartert, M.; Jacquemond-Collet, I.; Priem, F.; Sanchez, C.; Lambert, C.; Henrotin, Y. Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm. Res. 2009, 58, 899-908.
97. Ameye, L.G.; Chee, W.S. Osteoarthritis and nutrition. From nutraceuticals to functional foods: A systematic review of the scientific evidence. Arthritis Res. Ther. 2006, 8, R127.
98. Aggarwal, B.B.; Shishodia, S. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: Reasoning for seasoning. Ann. N. Y. Acad. Sci. 2004, 1030, 434-441.
99. Mobasheri, A. Intersection of inflammation and herbal medicine in the treatment of osteoarthritis. Curr. Rheumatol. Rep. 2012, 14, 604-616.
100. Goldring, M.B.; Marcu, K.B. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res. Ther. 2009, 11, 224.
101. Aigner, T.; Soder, S.; Gebhard, P.M.; McAlinden, A.; Haag, J. Mechanisms of disease: Role of chondrocytes in the pathogenesis of osteoarthritis-Structure, chaos and senescence. Nat. Clin. Pract. Rheumatol. 2007, 3, 391-399.
102. Pelletier, J.P.; Martel-Pelletier, J.; Abramson, S.B. Osteoarthritis, an inflammatory disease: Potential implication for the selection of new therapeutic targets. Arthritis Rheum. 2001, 44, 1237-1247.
103. Benito, M.J.; Veale, D.J.; FitzGerald, O.; van den Berg, W.B.; Bresnihan, B. Synovial tissue inflammation in early and late osteoarthritis. Ann. Rheum. Dis. 2005, 64, 1263-1267.
104. Kapoor, M.; Martel-Pelletier, J.; Lajeunesse, D.; Pelletier, J.P.; Fahmi, H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 2011, 7, 33-42.
105. Jerosch, J. Effects of glucosamine and chondroitin sulfate on cartilage metabolism in OA: Outlook on other nutrient partners especially omega-3 fatty acids. Inter. J. Rheumatol. 2011, 2011, 969012.
106. Milentijevic, D.; Rubel, I.F.; Liew, A.S.; Helfet, D.L.; Torzilli, P.A. An in vivo rabbit model for cartilage trauma: A preliminary study of the influence of impact stress magnitude on chondrocyte death and matrix damage. J. Orthop. Trauma. 2005, 19, 466-473.
107. Fernandes, J.C.; Martel-Pelletier, J.; Pelletier, J.P. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002, 39, 237-246.
108. Roman-Blas, J.A.; Jimenez, S.A. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthr. Cartilage 2006, 14, 839-848.
109. Saklatvala, J. Inflammatory signaling in cartilage: MAPK and NF-kappaB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis. Curr. Drug Targets 2007, 8, 305-313.
110. Blom, A.B.; Brockbank, S.M.; van Lent, P.L.; van Beuningen, H.M.; Geurts, J.; Takahashi, N.; van der Kraan, P.M.; van de Loo, F.A.; Schreurs, B.W.; Clements, K.; et al. Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: Prominent role of Wnt-induced signaling protein 1. Arthritis Rheum. 2009, 60, 501-512.
111. Chadjichristos, C.; Ghayor, C.; Kypriotou, M.; Martin, G.; Renard, E.; Ala-Kokko, L.; Suske, G.; de Crombrugghe, B.; Pujol, J.P.; Galera, P. Sp1 and Sp3 transcription factors mediate interleukin-1 beta down-regulation of human type II collagen gene expression in articular chondrocytes. J. Biol. Chem. 2003, 278, 39762-39772.
112. Goldring, M.B.; Fukuo, K.; Birkhead, J.R.; Dudek, E.; Sandell, L.J. Transcriptional suppression by interleukin-1 and interferon-gamma of type II collagen gene expression in human chondrocytes. J. Cell Biochem. 1994, 54, 85-99.
113. Seguin, C.A.; Bernier, S.M. TNFalpha suppresses link protein and type II collagen expression in chondrocytes: Role of MEK1/2 and NF-kappaB signaling pathways. J. Cell Physiol. 2003, 197, 356-369.
114. Saklatvala, J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986, 322, 547-549.
115. Mengshol, J.A.; Vincenti, M.P.; Coon, C.I.; Barchowsky, A.; Brinckerhoff, C.E. Interleukin-1 induction of collagenase 3(matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: Differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 2000, 43, 801-811.
116. Lefebvre, V.; Peeters-Joris, C.; Vaes, G. Modulation by interleukin 1 and tumor necrosis factor alpha of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. Biochim. Biophys. Acta 1990, 1052, 366-378.
117. Tortorella, M.D.; Malfait, A.M.; Deccico, C.; Arner, E. The role of ADAM-TS4(aggrecanase-1) and ADAM-TS5(aggrecanase-2) in a model of cartilage degradation. Osteoarthr. Cartilage 2001, 9, 539-552.
118. Abramson, S.B. Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res. Ther. 2008, 10, S2.
119. Caron, J.P.; Fernandes, J.C.; Martel-Pelletier, J.; Tardif, G.; Mineau, F.; Geng, C.; Pelletier, J.P. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum. 1996, 39, 1535-1544.
120. Chevalier, X.; Goupille, P.; Beaulieu, A.D.; Burch, F.X.; Bensen, W.G.; Conrozier, T.; Loeuille, D.; Kivitz, A.J.; Silver, D.; Appleton, B.E. Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009, 61, 344-352.
121. Grunke, M.; Schulze-Koops, H. Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade. Ann. Rheum. Dis. 2006, 65, 555-556.
122. Fioravanti, A.; Fabbroni, M.; Cerase, A.; Galeazzi, M. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: A pilot study. Rheumatol. Int. 2009, 29, 961-965.
123. Magnano, M.D.; Chakravarty, E.F.; Broudy, C.; Chung, L.; Kelman, A.; Hillygus, J.; Genovese, M.C. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J. Rheumatol. 2007, 34, 1323-1327.
124. Renkiewicz, R.; Qiu, L.; Lesch, C.; Sun, X.; Devalaraja, R.; Cody, T.; Kaldjian, E.; Welgus, H.; Baragi, V. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum. 2003, 48, 1742-1749.
125. Hellio Le Graverand-Gastineau, M.P. OA clinical trials: Current targets and trials for OA. Choosing molecular targets: What have we learned and where we are headed? Osteoarthr. Cartilage 2009, 17, 1393-1401.
126. Loeser, R.F. The effects of aging on the development of osteoarthritis. HSS J. 2012, 8, 18-19.
127. Loeser, R.F. Aging processes and the development of osteoarthritis. Curr. Opin. Rheumatol. 2013, 25, 108-113.
128. Zhuo, Q.; Yang, W.; Chen, J.; Wang, Y. Metabolic syndrome meets osteoarthritis. Nat. Rev. Rheumatol. 2012, 8, 729-737.
129. Aigner, T.; Richter, W. OA in 2011: Age-related OA-A concept emerging from infancy? Nat. Rev. Rheumatol. 2012, 8, 70-72.
130. Martin, J.A.; Buckwalter, J.A. Post-traumatic osteoarthritis: The role of stress induced chondrocyte damage. Biorheology 2006, 43, 517-521.
131. Kotani, K.; Sakane, N.; Kamimoto, M.; Taniguchi, N. Levels of reactive oxygen metabolites in patients with knee osteoarthritis. Australas J. Ageing 2011, 30, 231-233.
132. Loeser, R.F.; Carlson, C.S.; Del Carlo, M.; Cole, A. Detection of nitrotyrosine in aging and osteoarthritic cartilage: Correlation of oxidative damage with the presence of interleukin-1beta and with chondrocyte resistance to insulin-like growth factor 1. Arthritis Rheum. 2002, 46, 2349-2357.
133. Scott, J.L.; Gabrielides, C.; Davidson, R.K.; Swingler, T.E.; Clark, I.M.; Wallis, G.A.; Boot-Handford, R.P.; Kirkwood, T.B.; Taylor, R.W.; Young, D.A. Superoxide dismutase downregulation in osteoarthritis progression and end-stage disease. Ann. Rheum. Dis. 2010, 69, 1502-1510.
134. Regan, E.A.; Bowler, R.P.; Crapo, J.D. Joint fluid antioxidants are decreased in osteoarthritic joints compared to joints with macroscopically intact cartilage and subacute injury. Osteoarthr. Cartilage 2008, 16, 515-521.
135. Moon, S.J.; Woo, Y.J.; Jeong, J.H.; Park, M.K.; Oh, H.J.; Park, J.S.; Kim, E.K.; Cho, M.L.; Park, S.H.; Kim, H.Y.; et al. Rebamipide attenuates pain severity and cartilage degeneration in a rat model of osteoarthritis by downregulating oxidative damage and catabolic activity in chondrocytes. Osteoarthr. Cartilage 2012, 20, 1426-1438.
136. Ramakrishnan, P.; Hecht, B.A.; Pedersen, D.R.; Lavery, M.R.; Maynard, J.; Buckwalter, J.A.; Martin, J.A. Oxidant conditioning protects cartilage from mechanically induced damage. J. Orthop. Res. 2010, 28, 914-920.
137. Woo, Y.J.; Joo, Y.B.; Jung, Y.O.; Ju, J.H.; Cho, M.L.; Oh, H.J.; Jhun, J.Y.; Park, M.K.; Park, J.S.; Kang, C.M.; et al. Grape seed proanthocyanidin extract ameliorates monosodium iodoacetate-induced osteoarthritis. Exp. Mol. Med. 2011, 43, 561-570.
138. Rasheed, Z.; Akhtar, N.; Haqqi, T.M. Pomegranate extract inhibits the interleukin-1beta-induced activation of MKK-3, p38alpha-MAPK and transcription factor RUNX-2 in human osteoarthritis chondrocytes. Arthritis Res. Ther. 2010, 12, R195.
139. Garbacki, N.; Angenot, L.; Bassleer, C.; Damas, J.; Tits, M. Effects of prodelphinidins isolated from Ribes nigrum on chondrocyte metabolism and COX activity. Naunyn. Schmiedebergs. Arch. Pharmacol. 2002, 365, 434-441.
140. Shen, C.L.; Hong, K.J.; Kim, S.W. Effects of ginger(Zingiber officinale Rosc.) on decreasing the production of inflammatory mediators in sow osteoarthrotic cartilage explants. J. Med. Food 2003, 6, 323-328.
141. Thomson, M.; Al-Qattan, K.K.; Al-Sawan, S.M.; Alnaqeeb, M.A.; Khan, I.; Ali, M. The use of ginger(Zingiber officinale Rosc.) as a potential anti-inflammatory and antithrombotic agent. Prostag. Leukotr. Ess. 2002, 67, 475-478.
142. Frondoza, C.G.; Sohrabi, A.; Polotsky, A.; Phan, P.V.; Hungerford, D.S.; Lindmark, L. An in vitro screening assay for inhibitors of proinflammatory mediators in herbal extracts using human synoviocyte cultures. In Vitro Cell Dev. Biol. Anim. 2004, 40, 95-101.
143. Shakibaei, M.; Csaki, C.; Nebrich, S.; Mobasheri, A. Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: Potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem. Pharmacol. 2008, 76, 1426-1439.
144. Csaki, C.; Keshishzadeh, N.; Fischer, K.; Shakibaei, M. Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem. Pharmacol. 2008, 75, 677-687.
145. Shakibaei, M.; John, T.; Seifarth, C.; Mobasheri, A. Resveratrol inhibits IL-1 beta-induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes in vitro. Ann. N. Y. Acad. Sci. 2007, 1095, 554-563.
146. Schulze-Tanzil, G.; Mobasheri, A.; Sendzik, J.; John, T.; Shakibaei, M. Effects of curcumin(diferuloylmethane) on nuclear factor kappaB signaling in interleukin-1beta-stimulated chondrocytes. Ann. N. Y. Acad. Sci. 2004, 1030, 578-586.
147. Sreejayan, N.; Rao, M.N. Free radical scavenging activity of curcuminoids. Arzneimittelforschung 1996, 46, 169-171.
148. Chan, P.S.; Caron, J.P.; Orth, M.W. Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate. J. Rheumatol. 2006, 33, 1329-1340.
149. Largo, R.; Alvarez-Soria, M.A.; Diez-Ortego, I.; Calvo, E.; Sanchez-Pernaute, O.; Egido, J.; Herrero-Beaumont, G. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthr. Cartilage 2003, 11, 290-298.
150. Henrotin, Y.; Deby-Dupont, G.; Deby, C.; De Bruyn, M.; Lamy, M.; Franchimont, P. Production of active oxygen species by isolated human chondrocytes. Br. J. Rheumatol. 1993, 32, 562-567.
151. Lo, Y.Y.; Wong, J.M.; Cruz, T.F. Reactive oxygen species mediate cytokine activation of c-Jun NH2-terminal kinases. J. Biol. Chem. 1996, 271, 15703-15707.
152. Song, D.U.; Jung, Y.D.; Chay, K.O.; Chung, M.A.; Lee, K.H.; Yang, S.Y.; Shin, B.A.; Ahn, B.W. Effect of drinking green tea on age-associated accumulation of Maillard-type fluorescence and carbonyl groups in rat aortic and skin collagen. Arch. Biochem. Biophys. 2002, 397, 424-429.
153. Bordoni, A.; Hrelia, S.; Angeloni, C.; Giordano, E.; Guarnieri, C.; Caldarera, C.M.; Biagi, P.L. Green tea protection of hypoxia/reoxygenation injury in cultured cardiac cells. J. Nutr. Biochem. 2002, 13, 103-111.
154. Katiyar, S.K.; Afaq, F.; Azizuddin, K.; Mukhtar, H. Inhibition of UVB-induced oxidative stress-mediated phosphorylation of mitogen-activated protein kinase signaling pathways in cultured human epidermal keratinocytes by green tea polyphenol -epigallocatechin-3-gallate. Toxicol. Appl. Pharmacol. 2001, 176, 110-117.
155. Meng, Q.; Velalar, C.N.; Ruan, R. Effects of epigallocatechin-3-gallate on mitochondrial integrity and antioxidative enzyme activity in the aging process of human fibroblast. Free Radic. Biol. Med. 2008, 44, 1032-1041.
156. Ippoushi, K.; Azuma, K.; Ito, H.; Horie, H.; Higashio, H. [6]-Gingerol inhibits nitric oxide synthesis in activated J774.1 mouse macrophages and prevents peroxynitrite-induced oxidation and nitration reactions. Life Sci. 2003, 73, 3427-3437.
157. Pan, M.H.; Hsieh, M.C.; Hsu, P.C.; Ho, S.Y.; Lai, C.S.; Wu, H.; Sang, S.; Ho, C.T. 6-Shogaol suppressed lipopolysaccharide-induced up-expression of iNOS and COX-2 in murine macrophages. Mol. Nutr. Food Res. 2008, 52, 1467-1477.
158. Seeram, N.P.; Nair, M.G. Inhibition of lipid peroxidation and structure-activity-related studies of the dietary constituents anthocyanins, anthocyanidins, and catechins. J. Agric. Food Chem. 2002, 50, 5308-5312.
159. Sudheesh, S.; Vijayalakshmi, N.R. Flavonoids from Punica granatum-Potential antiperoxidative agents. Fitoterapia 2005, 76, 181-186.
160. Ahmed, S.; Wang, N.; Lalonde, M.; Goldberg, V.M.; Haqqi, T.M. Green tea polyphenol epigallocatechin-3-gallate(EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. J. Pharmacol. Exp. Ther. 2004, 308, 767-773.
161. Vankemmelbeke, M.N.; Jones, G.C.; Fowles, C.; Ilic, M.Z.; Handley, C.J.; Day, A.J.; Knight, C.G.; Mort, J.S.; Buttle, D.J. Selective inhibition of ADAMTS-1, -4 and -5 by catechin gallate esters. Eur. J. Biochem. 2003, 270, 2394-2403.
162. Yun, H.J.; Yoo, W.H.; Han, M.K.; Lee, Y.R.; Kim, J.S.; Lee, S.I. Epigallocatechin-3-gallate suppresses TNF-alpha-induced production of MMP-1 and -3 in rheumatoid arthritis synovial fibroblasts. Rheumatol. Int. 2008, 29, 23-29.
163. Lee, J.H.; Chung, J.H.; Cho, K.H. The effects of epigallocatechin-3-gallate on extracellular matrix metabolism. J. Dermatol. Sci. 2005, 40, 195-204.
164. Cheng, X.W.; Kuzuya, M.; Kanda, S.; Maeda, K.; Sasaki, T.; Wang, Q.L.; Tamaya-Mori, N.; Shibata, T.; Iguchi, A. Epigallocatechin-3-gallate binding to MMP-2 inhibits gelatinolytic activity without influencing the attachment to extracellular matrix proteins but enhances MMP-2 binding to TIMP-2. Arch. Biochem. Biophys. 2003, 415, 126-132.
165. Shakibaei, M.; John, T.; Schulze-Tanzil, G.; Lehmann, I.; Mobasheri, A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochem. Pharmacol. 2007, 73, 1434-1445.
166. Clutterbuck, A.L.; Mobasheri, A.; Shakibaei, M.; Allaway, D.; Harris, P. Interleukin-1beta-induced extracellular matrix degradation and glycosaminoglycan release is inhibited by curcumin in an explant model of cartilage inflammation. Ann. N. Y. Acad. Sci. 2009, 1171, 428-435.
167. Buhrmann, C.; Mobasheri, A.; Busch, F.; Aldinger, C.; Stahlmann, R.; Montaseri, A.; Shakibaei, M. Curcumin modulates nuclear factor kappaB(NF-kappaB)-mediated inflammation in human tenocytes in vitro: Role of the phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 2011, 286, 28556-28566.